Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk
JCO Precision Oncology · 2026-11 · 10 (11)
DOI: 10.1200/po-26-00974 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-11. Verfasst von Kristin Kohler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ambry Genetics, Aliso Viejo, CA. Hauptthemen laut MEDLINE: Epithelial Cell Adhesion Molecule, Colorectal Neoplasms, Hereditary Nonpolyposis, Gene Deletion. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
To characterize the cancer phenotype and clinical presentation across molecularly distinct EPCAM deletion subgroups and determine how the phenotype varies with MSH2 involvement.
Methods
We retrospectively evaluated 662 unrelated probands undergoing hereditary cancer multigene panel testing (MGPT) with isolated EPCAM full-gene deletions (n = 22), isolated EPCAM 3' deletions (n = 96), contiguous EPCAM full-gene deletions extending into MSH2 (n = 64), contiguous EPCAM 3' deletions extending into MSH2 (n = 116), MSH2 gross deletions (n = 155), and MSH2 nonsense/frameshift (ns/fs) variants (n = 209). Lynch syndrome (LS)–associated cancer prevalence, tumor spectrum, and PREMM5 scores were compared across cohorts. Multivariable logistic regression estimated cancer-specific associations relative to a MGPT-negative reference cohort.
Results
Isolated EPCAM full-gene deletions, comprising 18.6% of observed isolated EPCAM deletions, were not significantly associated with LS-associated cancers. The LS-associated cancer prevalence was 13.6% in this cohort, compared with 54.6% with isolated EPCAM 3' deletions and 64.1%-72.2% in MSH2 -involving cohorts ( P < .001). Relative to MGPT-negative individuals, isolated EPCAM 3' deletions were strongly associated with colorectal cancer (odds ratio [OR], 17.59; P < .001) but not endometrial cancer (OR, 0.76; P = .790). MSH2 -involving cohorts demonstrated strong associations with both colorectal (ORs, 8.50-16.03; P < .001) and endometrial cancers (ORs, 17.31-30.47; P < .001).
Conclusion
These findings provide new insights into the molecular and clinical heterogeneity of germline deletions involving EPCAM . Expanded detection across the full EPCAM gene and its 3' region distinguishes isolated full-gene deletions, which do not disrupt downstream MSH2 and are not associated with LS phenotypes, from isolated 3' deletions with a colorectal-predominant phenotype, and contiguous EPCAM-MSH2 deletions with an MSH2 -like LS phenotype. Precise delineation of EPCAM deletion boundaries and MSH2 involvement define three clinically relevant risk groups and support more precise risk assessment, counseling, and surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ambry Genetics, Aliso Viejo, CA.
- Division of Clinical Cancer Genomics, City of Hope, Duarte, CA.
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA.
ORCID-Profile: Kristin Kohler, Ashley P L Marsh, Carolyn Horton, John Michael O Ranola, Heather Hampel, Michael J Hall
Zitieren
APA
Kohler, K., Marsh, A. P. L., Hernandez, F., Horton, C., Ranola, J. M. O., Hampel, H., & Hall, M. J. (2026). Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk. JCO Precision Oncology, 10(11). https://doi.org/10.1200/po-26-00974
Vancouver
Kohler K, Marsh APL, Hernandez F, Horton C, Ranola JMO, Hampel H, et al. Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk. JCO Precision Oncology. 2026;10(11). doi:10.1200/po-26-00974
BibTeX
@article{Kohler2026,
author = {Kohler, Kristin and Marsh, Ashley P L and Hernandez, Felicia and Horton, Carolyn and Ranola, John Michael O and Hampel, Heather and Hall, Michael J},
title = {Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {11},
doi = {10.1200/po-26-00974}
}
EUVIMED